ENBI — Entheon Biomedical Cashflow Statement
0.000.00%
Last trade - 00:00
- CA$1.42m
- CA$1.07m
- CA$0.25m
2019 March 31st | 2020 March 31st | 2021 November 30th | 2022 November 30th | 2023 November 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -0.158 | -0.147 | -8.89 | -2.06 | -0.3 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 0.052 | 0.036 | 2.35 | 0.156 | -0.003 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -0.043 | 0.008 | 0.437 | 0.437 | -0.057 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | -0.221 | -0.102 | -5.62 | -1.47 | -0.36 |
Capital Expenditures | -0.411 | -0.085 | -0.098 | — | — |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | -0.001 | 0.609 | 0.024 |
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.411 | -0.085 | -0.099 | 0.609 | 0.024 |
Financing Cash Flow Items | -0.16 | 0.095 | — | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 1.51 | 0.095 | 4.98 | 0 | — |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.88 | -0.092 | -0.738 | -0.857 | -0.336 |